Jonathan Wolleben
Stock Analyst at Phillip Securities
(4.27)
# 1,377
Out of 4,667 analysts
168
Total ratings
49.67%
Success rate
16.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPOT Spotify Technology | Downgrades: Accumulate | $420 → $485 | $470.01 | +3.19% | 1 | Nov 13, 2024 | |
| SVRA Savara | Reiterates: Market Outperform | $9 | $3.13 | +187.54% | 7 | Oct 1, 2024 | |
| CRNX Crinetics Pharmaceuticals | Reiterates: Market Outperform | $80 | $56.07 | +42.68% | 12 | Sep 27, 2024 | |
| ALLK Allakos | Reiterates: Market Outperform | $3 | $0.94 | +219.42% | 6 | Sep 26, 2024 | |
| DBVT DBV Technologies | Reiterates: Market Outperform | $5 | $0.51 | +884.25% | 10 | Sep 24, 2024 | |
| RYTM Rhythm Pharmaceuticals | Initiates: Market Outperform | $64 | $59.36 | +7.82% | 1 | Sep 17, 2024 | |
| AURA Aura Biosciences | Maintains: Market Outperform | $19 → $23 | $8.75 | +162.86% | 6 | Sep 13, 2024 | |
| SKYE Skye Bioscience | Initiates: Market Outperform | $15 | $4.28 | +250.47% | 1 | Sep 10, 2024 | |
| SGMT Sagimet Biosciences | Maintains: Market Outperform | $48 → $32 | $4.52 | +607.96% | 8 | Aug 15, 2024 | |
| GPCR Structure Therapeutics | Maintains: Market Outperform | $91 → $86 | $32.71 | +162.92% | 6 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $45 → $43 | $40.65 | +5.78% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $15 → $16 | $7.30 | +119.18% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $381 → $385 | $317.09 | +21.42% | 10 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $66 → $68 | $43.69 | +55.64% | 8 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $25 | $6.08 | +311.18% | 11 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $25 → $24 | $8.05 | +198.14% | 10 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $24 → $22 | $8.78 | +150.57% | 16 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.99 | +704.75% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $49 → $50 | $20.50 | +143.90% | 9 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $3 | $0.49 | +512.24% | 6 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $1.05 | +376.19% | 9 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.67 | +63.49% | 6 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $33.67 | -28.72% | 1 | May 12, 2023 |
Spotify Technology
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $470.01
Upside: +3.19%
Savara
Oct 1, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $3.13
Upside: +187.54%
Crinetics Pharmaceuticals
Sep 27, 2024
Reiterates: Market Outperform
Price Target: $80
Current: $56.07
Upside: +42.68%
Allakos
Sep 26, 2024
Reiterates: Market Outperform
Price Target: $3
Current: $0.94
Upside: +219.42%
DBV Technologies
Sep 24, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $0.51
Upside: +884.25%
Rhythm Pharmaceuticals
Sep 17, 2024
Initiates: Market Outperform
Price Target: $64
Current: $59.36
Upside: +7.82%
Aura Biosciences
Sep 13, 2024
Maintains: Market Outperform
Price Target: $19 → $23
Current: $8.75
Upside: +162.86%
Skye Bioscience
Sep 10, 2024
Initiates: Market Outperform
Price Target: $15
Current: $4.28
Upside: +250.47%
Sagimet Biosciences
Aug 15, 2024
Maintains: Market Outperform
Price Target: $48 → $32
Current: $4.52
Upside: +607.96%
Structure Therapeutics
Aug 9, 2024
Maintains: Market Outperform
Price Target: $91 → $86
Current: $32.71
Upside: +162.92%
Aug 7, 2024
Maintains: Market Outperform
Price Target: $45 → $43
Current: $40.65
Upside: +5.78%
Aug 6, 2024
Maintains: Market Outperform
Price Target: $15 → $16
Current: $7.30
Upside: +119.18%
Jul 16, 2024
Maintains: Market Outperform
Price Target: $381 → $385
Current: $317.09
Upside: +21.42%
Jun 18, 2024
Maintains: Market Outperform
Price Target: $66 → $68
Current: $43.69
Upside: +55.64%
May 31, 2024
Reiterates: Market Outperform
Price Target: $25
Current: $6.08
Upside: +311.18%
May 10, 2024
Maintains: Market Outperform
Price Target: $25 → $24
Current: $8.05
Upside: +198.14%
May 8, 2024
Maintains: Market Outperform
Price Target: $24 → $22
Current: $8.78
Upside: +150.57%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.99
Upside: +704.75%
Apr 11, 2024
Maintains: Market Outperform
Price Target: $49 → $50
Current: $20.50
Upside: +143.90%
Mar 14, 2024
Maintains: Market Outperform
Price Target: $8 → $3
Current: $0.49
Upside: +512.24%
Mar 13, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $1.05
Upside: +376.19%
May 17, 2023
Reiterates: Market Outperform
Price Target: $6
Current: $3.67
Upside: +63.49%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $33.67
Upside: -28.72%